Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction.

Spriet I, Grootaert V, Meyfroidt G, Debaveye Y, Willems L.

Eur J Clin Pharmacol. 2013 Mar;69(3):737-8. doi: 10.1007/s00228-012-1365-8. No abstract available.

PMID:
22878691
2.

Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.

Berge M, Guillemain R, Boussaud V, Pham MH, Chevalier P, Batisse A, Amrein C, Dannaoui E, Loriot MA, Lillo-Le Louet A, Billaud EM.

Transpl Infect Dis. 2009 Jun;11(3):211-9. doi: 10.1111/j.1399-3062.2009.00384.x.

PMID:
19302272
3.

Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation.

Mori T, Kato J, Yamane A, Sakurai M, Kohashi S, Kikuchi T, Ono Y, Okamoto S.

Int J Hematol. 2012 May;95(5):564-9. doi: 10.1007/s12185-012-1057-2.

PMID:
22461034
4.

Intravenous voriconazole after toxic oral administration.

Alffenaar JW, van Assen S, de Monchy JG, Uges DR, Kosterink JG, van der Werf TS.

Antimicrob Agents Chemother. 2010 Jun;54(6):2741-2. doi: 10.1128/AAC.01193-09.

5.

Voriconazole-associated severe hyponatremia.

Kim KH, Lee S, Lee S, Yun NR, Kim NJ, Yu KS, Jang IJ, Park WB, Oh MD.

Med Mycol. 2012 Jan;50(1):103-5. doi: 10.3109/13693786.2011.587210.

PMID:
21671829
6.

Highly activated oral bioavailability of tacrolimus on coadministration of oral voriconazole.

Inoue Y, Saito T, Takimoto M, Ogawa K, Shibuya Y, Suzuki Y, Kato M, Takahashi M, Miura I, Hatta Y, Takeuchi J.

Int J Clin Pharmacol Ther. 2011 Apr;49(4):291-2. doi: 10.5414/CPP49291. No abstract available.

7.

Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient.

Capone D, Tarantino G, Gentile A, Sabbatini M, Polichetti G, Santangelo M, Nappi R, Ciotola A, D'Alessandro V, Renda A, Basile V, Federico S.

J Clin Pharm Ther. 2010 Feb;35(1):121-4. doi: 10.1111/j.1365-2710.2009.01070.x.

PMID:
20175821
8.

Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus.

Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG.

Pharmacotherapy. 2007 Jun;27(6):825-34.

PMID:
17542765
9.

An alternative approach to determine oral bioavailability of drugs that follow Michaelis-Menten elimination: a case study with voriconazole.

Verlindo de Araujo B, Farias da Silva C, Costa TD.

Pharmacology. 2010;86(3):163-7. doi: 10.1159/000317066.

PMID:
20714206
10.

Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.

Thomas A, Korb V, Guillemain R, Caruba T, Boussaud V, Billaud E, Prognon P, Begué D, Sabatier B.

J Clin Pharm Ther. 2010 Feb;35(1):49-53. doi: 10.1111/j.1365-2710.2009.01061.x.

PMID:
20175811
11.

Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens.

Burhenne J, Haefeli WE, Hess M, Scope A.

J Avian Med Surg. 2008 Sep;22(3):199-207.

PMID:
19014092
12.

Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.

Clifton IJ, Whitaker P, Metcalfe R, Phillip M, Shaw N, Conway SP, Peckham DG.

J Antimicrob Chemother. 2011 Oct;66(10):2438-40. doi: 10.1093/jac/dkr300. No abstract available.

PMID:
21791443
13.

Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients.

Peng LW, Lien YH.

Am J Kidney Dis. 2005 Jan;45(1):162-6.

PMID:
15696456
14.

Plasma concentrations of voriconazole in falcons.

Schmidt V, Demiraj F, Di Somma A, Bailey T, Ungemach FR, Krautwald-Junghanns ME.

Vet Rec. 2007 Aug 25;161(8):265-8.

PMID:
17720963
15.

Safety of voriconazole and dose individualization.

Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND.

Clin Infect Dis. 2003 Apr 15;36(8):1087-8. No abstract available.

PMID:
12684928
16.

Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.

Mohammedi I, Piens MA, Padoin C, Robert D.

Eur J Clin Microbiol Infect Dis. 2005 May;24(5):358-60. No abstract available.

PMID:
15875225
17.

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O.

Clin Infect Dis. 2008 Jan 15;46(2):201-11. doi: 10.1086/524669.

PMID:
18171251
18.

Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis.

Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, Cotton MP, Stergiopoulou T, Kasai M, Francesconi A, Schaufele RL, Sein T, Avila NA, Bacher J, Walsh TJ.

Antimicrob Agents Chemother. 2009 Jun;53(6):2382-91. doi: 10.1128/AAC.00329-09.

19.

A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Frechen S, Junge L, Saari TI, Suleiman AA, Rokitta D, Neuvonen PJ, Olkkola KT, Fuhr U.

Clin Pharmacokinet. 2013 Sep;52(9):763-81. doi: 10.1007/s40262-013-0070-9.

PMID:
23653047
20.

[Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis].

Hagiwara E, Shiihara J, Matsushima A, Enomoto T, Tagawa A, Sekine A, Tsuchiya N, Baba T, Shinohara T, Endo T, Sogo Y, Nishihira R, Komatsu S, Kato T, Ogura T, Takahashi H.

Nihon Kokyuki Gakkai Zasshi. 2009 Feb;47(2):93-7. Japanese.

PMID:
19260530

Supplemental Content

Support Center